Currently Viewing:
Evidence-Based Oncology July 2017
Daratumumab With Standard Regimen Improves PFS, ORR Independent of Cytogenetic Risk in Multiple Myeloma
Surabhi Dangi-Garimella, PhD
Phase 1 Study Results at ASCO Support First-Line Use of Daratumumab in Multiple Myeloma
Surabhi Dangi-Garimella, PhD
Daratumumab-Based Combination Effective in Relapsed/Refractory Multiple Myeloma, Short PFS in Heavily Pretreated Patients
Surabhi Dangi-Garimella, PhD
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
Surabhi Dangi-Garimella, PhD
An Early Stage Safety, Efficacy Study for Atezolizumab Plus Daratumumab in Advanced NSCLC
Surabhi Dangi-Garimella, PhD
LDH Levels Could Predict irAEs Associated With Checkpoint Inhibition and Radiotherapy in Lung Cancer
Surabhi Dangi-Garimella, PhD
Alectinib May Be a New Standard of Care for Treatment-Naïve ALK-Positive NSCLC
AJMC Staff
Dacomitinib a New First-Line Option for Advanced EGFR Mutation—Positive NSCLC
AJMC Staff
Androgen Deprivation, With or Without Radiotherapy, New Standard of Care in High-Risk Prostate Cancer
AJMC Staff
Trabectedin and Lurbinectedin Effective in BRCA2-Associated Metastatic Breast Cancer
AJMC Staff
HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults
Surabhi Dangi-Garimella, PhD
Physical Activity, Healthy Diet Improve Survival in Colorectal Cancer: Study at ASCO
Surabhi Dangi-Garimella, PhD
Three Months of Oxaliplatin-Based Adjuvant Therapy Noninferior to 6 Months in Stage III Colon Cancer
AJMC Staff
Fas Biomarker Can Predict Response to Second-Line Therapy for Advanced Soft Tissue Sarcoma
AJMC Staff
Nivolumab, Alone or With Ipilimumab, Met the Disease Control Rate in Malignant Pleural Mesothelioma
AJMC Staff
Ibrutinib vs No Consolidation Are Being Compared Following Autologous HSCT in IRONCLAD Trial
AJMC Staff
Web-Based Patient Reporting of Symptoms Shown to Improve Survival in Patients With Metastatic Solid Tumors
AJMC Staff
Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data
Surabhi Dangi-Garimella, PhD
Currently Reading
Do We Have Adequate Surveillance in Cancer Care?
Surabhi Dangi-Garimella, PhD
ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation
Surabhi Dangi-Garimella, PhD
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
Surabhi Dangi-Garimella, PhD
Research Demonstrates Efficacy and Safety of Trastuzumab Biosimilar SB3
Kelly Davio
CT-P6, a Trastuzumab Biosimilar, Shares the Safety and Efficacy Profile of Its Reference
Kelly Davio
Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?
Surabhi Dangi-Garimella, PhD
Adjuvant Chemotherapy Reduces Cost, Improves Survival in NSCLC Post-Surgery
Surabhi Dangi-Garimella, PhD
Brazilian Study Queries: Is NGS Cost-Effective in Advanced Lung Cancer?
Surabhi Dangi-Garimella, PhD
SEER-Medicare Database Analysis Notes Higher Resource Utilization Among Patients With Neuroendocrine Tumors
Surabhi Dangi-Garimella, PhD

Do We Have Adequate Surveillance in Cancer Care?

Surabhi Dangi-Garimella, PhD
A poster discussion session at the 2017 Annual Meeting of the American Society of Clinical Oncology led by Katherine Van Loon, MD, MPH, examined retrospective surveillance data in 3 cancers: non—small cell lung cancer, head and neck cancer, and colorectal cancer.
SURVIVORSHIP CARE IS IMPORTANT among patients who have undergone treatment for cancer, and follow-up can help them discuss issues that may be associated with their treatment, share their financial concerns, and, most importantly, ensure disease-free survival. A poster discussion session at the 2017 Annual Meeting of the American Society of Clinical Oncology examined retrospective surveillance data in 3 cancers: non–small cell lung cancer (NSCLC), head and neck cancer (HNC), and colorectal cancer (CRC). Katherine Van Loon, MD, MPH, from the University of California, San Francisco, led the discussion.

Head and Neck Cancer
The first study,1 conducted by researchers affiliated with multiple healthcare systems in Philadelphia, evaluated the impact of radiation therapy and a latency period on the risk of developing new primary lung cancers after HNC. The population-based study of 85,154 patients with HNC in the Surveillance, Epidemiology, and End Results (SEER) database found 4209 patients with new primary lung cancers. Compared with the no radiation group, those who received radiation therapy had a higher incidence of primary lung cancers across all latency periods: from less than 1 year of follow-up (standardized incidence ratio [SIR], 3.45 vs 2.18, respectively) to 10 to 15 years (SIR, 3.19 vs 1.88). The highest incidence for the radiation-treated group was observed in the 1-to-3-year latency period (4.57 vs 2.41).

The authors concluded that in patients with HNC, the risk of developing a new primary lung cancer is associated with radiation treatment, with the greatest risk observed within 10 years of the initial HNC diagnosis. They recommended that screening for patients who smoke should be considered, especially within 10 years of the primary HNC diagnosis.

Van Loon said that while the large sample size from the SEER data was a significant strength of the study, retrospective analysis placed limitations on the observations. Further, the predominance of squamous cell carcinoma raised questions on de-novo versus metastatic nature of the observed lung cancer. She also pointed out the lack of data on patient exposure to risk factors as a study limitation.

Colorectal Cancer
The next study2 evaluated the impact of posttreatment surveillance in CRC, with the purpose being to determine if the surveillance is associated with time to recurrence detection, treatment, or overall survival (OS). The authors examined the primary records of 10,636 stage I to III patients with CRC from Commission on Cancer-accredited hospitals who were diagnosed between 2006 and 2007; data were merged with records in the National Cancer Database. A predicted and observed number of imaging and carcinoembryonic antigen (CEA) tests per patient were determined and clustered by hospital; patients were then categorized into high- or low-intensity categories.

Of the 6279 patients, those who underwent high-intensity imaging (50.6%) or CEA surveillance (51.2%) in the 3 years after CRC treatment had a mean of 2.9 imaging studies and 4.7 CEA tests. Patients with low-intensity imaging underwent a mean of 1.4 imaging studies and 1.6 CEA tests. Patients’ 5-year recurrence rates were no different based on the intensity of surveillance: stage II and stage III patients who underwent high-intensity imaging and CEA testing had a slightly higher resection rate, without any improvement in the 5-year OS.

The authors concluded that higher-intensity surveillance was not associated with earlier detection of recurrent disease or improved OS. It did, however, result in a slightly higher resection rate. They went on to recommend less frequent testing for surveillance in patients with CRC.

Van Loon praised the highly annotated design and large real-world sample of patients used by the trial. “The findings add to results of [the] FACS and GILDA trials, so intensive follow-up may not improve OS for CRC survivors,” she added. Questions remain about whether a subset of patients with recurrence may benefit from more intensive surveillance, she concluded.

Lung Cancer
The final abstract3 discussed was the receipt of recommended surveillance with imaging in survivors of early stage NSCLC. Lifelong imaging surveillance for early cancer detection is recommended in lung cancer survivors who have a high risk for recurrence and second cancers and a 5-year survival of 50%. The study authors examined the rates and determinants of regular surveillance imaging in NSCLC survivors.

Examination of the SEER-Medicare linked database identified 10,680 patients with stage I and II NSCLC diagnosed over the 10 years between 2001 and 2011 and treated with surgery. Patients were censored at the time of recurrence/second cancer, loss of insurance, or 3 months before death. In this population, receipt of computerized tomography and/or positron emission tomography imaging during the surveillance periods of 7 to 18, 19 to 30, 31 to 42, and 43 to 60 months from the date of surgery was assessed.

The study found that 79% and 40% of survivors had follow-up information until the end of the 30- and 60-month surveillance periods, respectively. With a median follow-up of 7.6 years, 71% of the survivors received imaging in the first 18 months after surgery, but only 56% and 44% of survivors continued to receive regular imaging by the 30- and 60-month of follow-up periods, respectively.

Survivors, the analysis found, were less likely to receive imaging if they were older (≥80 years), black, not married, lived in a rural location, did not receive adjuvant therapy, had stage I disease (compared with stage II), and received their diagnosis in 2006 or earlier. In adjusted analysis, survivors receiving recommended imaging up to 18 months post-surgery had improved survival compared with survivors who did not (HR, 0.86; 95% CI, 0.81-0.92). Survival benefit was also observed in survivors who had regular imaging up to 5 years from surgery (HR, 0.68; 95% CI, 0.60-0.76).

The fact that more than 50% of the lung cancer survivors did not receive recommended long-term surveillance imaging had the authors conclude that adherence to regular surveillance, even 5 years from the initial surgery, is associated with improved survival. Van Loon noted that the large cohort size was a definite plus for the study, as was the use of the SEER-Medicare linked database. The limitations of the study were that it was retrospective, was missing a population group younger than 66 years, and did not use non-Medicare sources. Additionally, 60% of patients were missing follow-up at 60 months.
REFERENCES

1. Jeurkar C, Pompa T, Bauman JR, et al. New primary lung cancers after a head and neck cancer: The impact of radiation therapy and latency period on risk. J Clin Oncol. 2017;35(suppl; abst 10015).

2. Snyder RA, Hu C, Cuddy A, et al. Impact of intensity of post-treatment surveillance on survival in colorectal cancer. J Clin Oncol. 2017;35(suppl; abst 10016).

3. Malhotra J, Rotter D, Jabbour S, at al. Receipt of recommended surveillance with imaging in survivors of early stage non-small cell lung cancer. J Clin Oncol. 2017;35(suppl; abst 10017).
PDF
 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!